TW202330034A - 抗ｔｉｇｉｔ抗體之臨床調配物 - Google Patents

抗ｔｉｇｉｔ抗體之臨床調配物 Download PDF

Info

Publication number
TW202330034A
TW202330034A TW111149551A TW111149551A TW202330034A TW 202330034 A TW202330034 A TW 202330034A TW 111149551 A TW111149551 A TW 111149551A TW 111149551 A TW111149551 A TW 111149551A TW 202330034 A TW202330034 A TW 202330034A
Authority
TW
Taiwan
Prior art keywords
cancer
monoclonal antibody
liquid pharmaceutical
seq
amino acid
Prior art date
Application number
TW111149551A
Other languages
English (en)
Chinese (zh)
Inventor
伊安 宗悌 謝
安 瑪莉 沃伊斯
凱薩琳 蘿拉 楚迪
羅賓 瑪麗亞 蘇林
魯查 蘇達卡 薩內
慧敏 陳
曉慧 溫
伊莎貝爾 安 魯尼
Original Assignee
美商建南德克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司 filed Critical 美商建南德克公司
Publication of TW202330034A publication Critical patent/TW202330034A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111149551A 2021-12-22 2022-12-22 抗ｔｉｇｉｔ抗體之臨床調配物 TW202330034A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163292863P 2021-12-22 2021-12-22
US63/292,863 2021-12-22
US202263383451P 2022-11-11 2022-11-11
US63/383,451 2022-11-11
US202263387229P 2022-12-13 2022-12-13
US63/387,229 2022-12-13

Publications (1)

Publication Number Publication Date
TW202330034A true TW202330034A (zh) 2023-08-01

Family

ID=85199491

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111149551A TW202330034A (zh) 2021-12-22 2022-12-22 抗ｔｉｇｉｔ抗體之臨床調配物

Country Status (10)

Country Link
US (1) US20240408009A1 (https=)
EP (1) EP4452320A1 (https=)
JP (1) JP2025500483A (https=)
KR (1) KR20240121771A (https=)
AU (1) AU2022417501A1 (https=)
CA (1) CA3242136A1 (https=)
IL (1) IL313658A (https=)
MX (1) MX2024007749A (https=)
TW (1) TW202330034A (https=)
WO (1) WO2023122665A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515614A (zh) 2023-08-25 2025-04-16 美商建南德克公司 治療非小細胞肺癌之方法及組成物
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
KR20220113414A (ko) 2019-12-09 2022-08-12 제넨테크, 인크. 항-pd-l1 항체 제제
CN115052622B (zh) * 2020-01-21 2026-03-06 夏尔巴生物技术(杭州)有限公司 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
TW202142230A (zh) * 2020-01-27 2021-11-16 美商建南德克公司 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法

Also Published As

Publication number Publication date
AU2022417501A1 (en) 2024-07-04
CA3242136A1 (en) 2023-06-29
IL313658A (en) 2024-08-01
MX2024007749A (es) 2024-07-01
JP2025500483A (ja) 2025-01-09
EP4452320A1 (en) 2024-10-30
WO2023122665A1 (en) 2023-06-29
US20240408009A1 (en) 2024-12-12
KR20240121771A (ko) 2024-08-09

Similar Documents

Publication Publication Date Title
JP7312188B2 (ja) 抗ｐｄ－１抗体組成物
US20230279096A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
KR20200112867A (ko) 길항적 항-pd-1 항체로 암을 치료하는 방법
US20240408009A1 (en) Clinical formulations of anti-tigit antibodies
JP7703513B2 (ja) 抗ガレクチン９抗体と化学療法剤の組合せがん治療
KR20170007750A (ko) Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
BR112021010789A2 (pt) Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
TW202346344A (zh) 以tl1a抑制劑及il23抑制劑的組合治療發炎疾病之方法
CN113747944A (zh) 用抗psma/cd3抗体治疗前列腺癌的方法
CN114026126A (zh) 抗半乳糖凝集素-9抗体及其用途
AU2021345124A1 (en) Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
CN115397861A (zh) 用于癌症的组合治疗
JP2023521228A (ja) 癌の併用療法
CN113747945A (zh) 用抗psma/cd3抗体治疗肾癌的方法
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
TW202241512A (zh) 結合ctla-4的抗體及其用途
KR20250029919A (ko) 갈렉틴-9를 억제하는 항체를 사용한 혈액학적 악성종양의 치료
RU2745814C1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
CN118871131A (zh) 抗tigit抗体的临床制剂
JP2026513259A (ja) 抗ｔｉｇｉｔ抗体を用いた腫瘍の治療方法
WO2023198115A1 (en) Stable high concentration sodium chloride formulations containing pd-1 antibody and methods of use thereof
WO2025085792A1 (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
RU2772781C2 (ru) Композиции анти-pd-1 антител
TW202509075A (zh) T細胞銜接蛋白治療癌症之用途
WO2023107100A1 (en) Methods and treatment for multiple myeloma involving antibodies to il-18